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Abstract 
Objective(s) 
This study aimed to examine whether acetyl-L-carnitine (ALC) was able to reduce cardiac arrhythmias and 
infarct size in the ischemic-reperfused isolated rat heart. 
Materials and Methods 
The isolated hearts were mounted on a Langendorff apparatus then perfused by a modified Krebs-Henseleit 
solution during 30 min regional ischemia and 120 min reperfusion (control) or by enriched Krebs solution 
with 0.375, 0.75, 1.5 and 3 mM of ALC (treatment groups). The ECGs were recorded and analyzed to 
determine cardiac arrhythmias. The infarct size was determined by using a computerized planimetry 
package. 
Results 
During ischemia, all used concentrations of ALC decreased number and duration of ventricular tachycardia 
(VT), total number of ventricular ectopic beats (VEBs) (P<0.01), incidence of total ventricular fibrillation 
(VF) and the time spent for reversible VF (P<0.05). At the reperfusion phase, duration of VT, incidence of 
total VF and reversible VF were significantly lowered by ALC (P<0.05). In addition, infarct size 
significantly was decreased in all treated groups. In the control group, the infarct size was 23±3.1%, 
however, ALC (0.375, 0.75 and 3 mM) reduced it to 8.7±2.3, 5.3±1.4, and 8±2.9%, respectively (P<0.01).  
Conclusion 
Considering the results, it may be concluded that ALC has protective effects against cardiac ischemia-
reperfusion (I/R) injuries by reduction of infarct size and arrhythmias in isolated rat heart. Among the potential 
cardioprotective mechanisms for ALC, increase in glucose oxidation and resulting reduced lactate 
production, reduction of toxic fatty acid metabolites and removing free radicals from the myocytes are more 
relevant.  
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Introduction 
Acetyl-L-carnitine (ALC) is an ester of the 
trimethylated amino acid, L-carnitine, and is 
synthesized in the human brain, liver, and 
kidney by the enzyme ALC transferase. ALC 
facilitates  the  uptake  of  acetyl  CoA                  
into the mitochondria during fatty acid 
oxidation, enhances acetylcholine production, 
and stimulates protein and membrane 
phospholipids synthesis (1). ALC plays a 
major role in normal mitochondrial function, 
being a transport molecule for free fatty acids 
and an important acetyl-group donor in high-
energy metabolism and free fatty acid beta-
oxidation (2, 3). Its main body stores are in 
skeletal and cardiac muscle. It is found along 
with free plasma L-carnitine and other acyl-
esters of varying chain length (4). The 
formation of ALC originates with cytoplasmic 
thiokinase which forms acyl-coenzyme A from 
free fatty acids, ATP and coenzyme A (CoA) 
(5). This substance is combined with carnitine 
to form acetyl-carnitine via carnitine 
palmitoyltransferase I. (5, 6). The enzymatic 
formation of ALC in the mitochondrial matrix 
is reversible, releasing free CoA and acetyl-
CoA which can readily be exchanged across 
membranes, thus providing metabolic energy 
to intracellular organelles. 
It is claimed that ALC provides several 
benefits in certain pathologies. There may be 
some benefit in cases of end stage renal 
disease or peripheral arterial disease (7). 
Lipoic acid when supplemented alongside 
ALC appears to reverse some of the damage to 
mitochondria associated with aging (8). ALC 
supplementation has been shown to be 
neuroprotective in instances of cerebral 
ischemia (9), peripheral nerve injury (10) and 
in the treatment of Parkinson's disease in 
animals (11). ALC supplementation has also 
been shown to reverse symptoms associated 
with mental decline in the elderly (12).
 ALC is 
being researched in the treatment of 
Alzheimer's disease (13). There is some 
evidence that L-carnitine (parent compound of 
ALC) supplementation may exert a 
cardioprotective role in cardiomyopathy, 
prevention of arrhythmias in myocardial 
infarction and increasing exercise tolerance in 
angina (14). Arsenian et al (1996) 
demonstrated a decrease in mortality and 
incidence of circulatory failure in a group of 
patients with acute myocardial infarction who 
were administered 3 g of L-carnitine along 
with solution of glucose, insulin, potassium 
and magnesium (15). In a study in 2003, 
effects of short time perfusion of L-carnitine 
and ALC on the incidence of reperfusion-
induced arrhythmias and infarct size were 
investigated in isolated rat heart in the setting 
of global ischemia. Results of the above study 
showed that perfusion of 0.05, 0.5 and 5 mM 
of L-carnitine and ALC for 10 min before 
induction of global ischemia failed to reduce 
the incidence of ventricular fibrillation (VF). 
In addition, infarct size was reduced only by 
high concentration (5 mM) of the agents (16). 
Despite the mentioned protective effects of 
ALC, its cardioprotective effects on 
myocardial infarction size and cardiac 
arrhythmias in the setting of regional ischemia 
(not global ischemia) are not completely 
understood. In the present study, effects of 
ALC perfusion for the whole period of 30 min 
regional ischemia followed by 120 min 
reperfusion (I/R) on myocardial infarction size 
and arrhythmias were investigated in isolated 
rat heart.  
 
Materials and Methods 
The following chemicals were purchased: 
ALC (Sigma Tau company), NaCl, NaHCO3, 
KCl, KH2PO4, MgSO4, CaCl2, D-glucose 
(Merck company), Sodium pentobarbital (Kela 
company, Belgium) and Heparin (Daru-pakhsh 
company, Iran). 
 
Animals and surgical procedure 
Male Wistar rats weighing 270-330 g were 
used in this study. The rats were pretreated 
with intra-peritoneal (ip) injection of 1000 
IU/kg heparin then anaesthetized by sodium 
pentobarbital (60 mg/kg, ip) (17). The hearts 
were  excised  rapidly  and  mounted  on  a           
non-recirculating langendorff apparatus under 
100 mmHg pressure at 37 °C and perfused 
throughout the experiments with modified 
Krebs-Henseleit (K/H) solution which was 
previously equilibrated with 95% O2-5% CO2. 
A fluid filled balloon was introduced into the  
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left ventricle and inflated to give a preload of 
8–10 mmHg (17, 18). After 20 min 
stabilization, the hearts were subjected to 30 
min regional ischemia followed by 120 min 
reperfusion. In the control group (n=8), the 
hearts were perfused only by normal K/H 
solution throughout the experiment, while in 
the treatment groups (4 groups, n=8 in each 
group), they were perfused with enriched K/H 
solution with 0.375, 0.75, 1.5 and 3 mM of 
ALC respectively during I/R. Induction of 
regional ischemia was achieved by temporary 
occlusion of left anterior descending (LAD) 
coronary artery followed by 120 min 
reperfusion (19, 20). An epicardial ECG was 
recorded by a polygraph during the 
experiment. Based on the Lambeth 
conventions, the ECGs were analyzed to 
determine the total number of ventricular 
ectopic beats (VEBs), the number of beats 
occurring as ventricular tachycardia (VT), and 
the incidence and duration of VT and VF 
during ischemia and the first 30 min of 
reperfusion time (20, 21). Animal procedure 
was approved by local ethics committee. 
 
Measurement of myocardial infarct size 
To determine the infarct size, at the end of 120 
min reperfusion period, the ligature around the 
LAD artery was re-tied and the heart was 
slowly perfused with 2-3 ml of saline solution 
containing 0.25% Evans blue dye (w/v) via the 
side arm of the aortic cannula (21). The hearts 
were frozen, and then the ventricles of the 
frozen hearts were sliced transversely in a 
plane perpendicular to the apico–basal axis 
into 2 mm thick sections. The slices were 
incubated with 1% (w/v) triphenyltetrazolium 
chloride (TTC) solution in phosphate buffer 
for 15 min at 37 °C to dye the non–infarcted 
region (21, 22). This procedure resulted in the 
normally perfused tissue being stained blue, 
non-infarcted, non-perfused tissue stained 
brick red, and infarcted tissue remaining 
unstained and appeared pale (23). 
 
Statistical analysis 
Except for the incidence of VT and VF which 
are expressed as percentage, all the other 
results are expressed as mean±SEM. To 
compare the number of VT, VEBs and 
duration of VT and VF between groups, the 
Mann-Whitney non-parametric U-test was 
employed. For analyzing the incidence of VT 
and VF, Fisher Irwin test (Chi-square with 
Yates correction) was used. The percentage of 
infarct size was analyzed using one way 
ANOVA and then considerable differences 
examined by LSD post hoc range test (19, 21). 
Differences between groups were considered 
significant at a level of P< 0.05. 
 
Results 
The effects of ALC on ischemic and 
reperfusion arrhythmias are summarized in 
Table 1 and 2. During ischemia, all used 
concentrations of ALC decreased number and 
duration of ischemic VT and number of 
ventricular ectopic beats (VEBs) versus the 
control group (P<0.01). ALC reduced the 
incidence of total ventricular fibrillation (VF) 
and the time spent for reversible VF (P<0.05). 
 
 
 
 
 
 
Table 1. Effects of ALC (0.375, 0.75, 1.5 and 3 mM) on cardiac arrhythmias during 30 min ischemia in isolated rat heart. 
 
Ischemia time   
VT 
incidence 
(%)   
Total VF  
incidence 
(%)   
Rev VF 
incidence   
(%)   
Rev VF   
duration  
(sec)   
VT duration  
(sec)   
VT  
number   
VEBs 
number  
 
Groups 
90   60   50   65±42   74±31   473±166
   941±224   Control 
71    0*    0*    0*    16±8   100±49*
   289±61**    ALC  (0.375 mM) 
57   0*   0*   0*    4±2**   23±10**   113±23**   ALC  (0.75 mM) 
86   0*   0*    0*   6±2*   37±12**   154±37**    ALC  (1.5 mM) 
43*   14   14   44±23   4±2**   23±14**   69±15**    ALC  (3 mM) 
*P<0.05, **P<0.01 versus the control group. N=8 rats in each group. VT: Ventricular Tachycardia, VEBs: Ventricular 
Ectopic Beats (Single+Salvos+VT), Rev VF: Reversible Ventricular Fibrillation, Irrev VF: Irreversible Ventricular 
Fibrillation.  
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Table 2. Effects of ALC (0.375, 0.75, 1.5 and 3 mM) on cardiac arrhythmias during 30 min reperfusion in isolated rat heart. 
 
Reperfusion time   
VT   
incidence   
(%)   
Total VF  
incidence 
(%)   
Rev VF   
incidence    
(%)   
Rev VF 
duration   
(sec)   
VT 
duration   
(sec)  
VT   
number   
VEBs 
number  
Groups   
80   90   80   60±29   7 ± 30    176±42   330±105    Control   
57   29*   14   171±171*   4±2**   24±17   70±28*   ALC (0.375 mM)   
71   57   43   105±72   18±12   110±75   187±77   ALC (0.75 mM)   
43   29*   0**   0**   9±7*   49±38   139±69   ALC (1.5 mM)    
57   29*   29   13±8*    31±20   179±125   254±154   ALC (3 mM)   
 
* P<0.05, **P<0.01 versus the control group. N=8 rats in each group. VT; Ventricular Tachycardia, VEBs; Ventricular 
Ectopic Beats (Single+Salvos+VT), Rev VF; Reversible Ventricular Fibrillation, Irrev VF; Irreversible Ventricular 
Fibrillation. 
 
In addition, incidence of VT was significantly 
reduced only by 3 mM concentration (P<0.05). 
During reperfusion phase, number of VEBs 
were reduced significantly mainly by lower 
concentrations (P<0.05). Also, reversible VF 
duration was decreased from 61±29 sec in the 
control group to 0 sec by 1.5 mM of ALC 
(P<0.01). As depicted in Table 2, duration of 
VT showed significant reduction by 0.375 and 
1.5 mM of ALC (P<0.01 and P<0.05, 
respectively). Moreover, as shown in Figure 1, 
ALC (0.375, 1.5 and 3 mM) reduced the 
incidence of total VF from 90% (control) to 
29% (P<0.05). The same concentrations of 
ALC also reduced the incidence of reversible 
VF from 80% to 14% (P<0.05), 0% (P<0.01) 
and 29% (P<0.05), respectively (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Incidence of total ventricular fibrillation (Total 
VF) and reversible VF (Rev VF) in the control and 
isolated rat hearts receiving Acetyl-L-carnitine during 30 
min reperfusion. *P< 0.05, **P< 0.01, versus the 
control group. n=8 rats in each group. 
 
In the control group, infarct size was 
23±3.1%, however, ALC (0.375, 0.75 and 3 
mM) reduced infarct size to 8.7±2.3, 5.3±1.4, 
and 8±2.9%, respectively (P<0.01) and ALC 
(1.5 mM)  reduced infarct size to 12±4 
(P<0.05) (Figure 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Myocardial infarct size in the control and 
isolated rat hearts receiving 0.375, 0.75, 1.5 and 3 mM 
of Acetyl-L-carnitine during 30 min ischemia followed 
by 120 min reperfusion. Data are represented as 
mean±SEM. **P< 0.01 versus control group. n=8 rats 
in each group. 
 
Discussion 
The most important cause of mortality in the 
course of cardiac surgery and myocardial 
infarction are ventricular arrhythmias such as 
VT and VF (24). The present study focused on 
the pharmacological effects of ALC on I/R- 
induced cardiac arrhythmias and infarct size in 
isolated rat heart. 
For the first time in the medical literature, 
the results of present study showed that ALC  
Moslem Najafi et al 
  Iran J Basic Med Sci, Vol. 13, No.1, Winter 2010    220 
produces antiarrhythmic effects against I/R-
induced arrhythmias such as VT, VEBs and 
VF. Perfusion of ALC produced significant 
reduction in the number and duration of 
ischemic VT, number of VEBs, duration and 
incidence of reversible VF and total VF in 
ischemia time. At the reperfusion phase, 
duration of VT, incidence of total VF and 
reversible VF were significantly lowered by 
ALC when it is used during 30 min regional 
ischemia and 30 min reperfusion.  
Our findings also demonstrated that ALC 
caused marked and potent protective activity 
against I/R injuries as reduction of infarct size 
in this model of study. 
ALC plays a fundamental role in the 
production and dissemination of cellular 
energy as well as in the regulation of 
metabolic pathways since it is a co-factor 
required for transport of long-chain fatty acids 
through the mitochondrial membrane (25). 
ALC also acts as a scavenger of free radicals 
in many cells (25). Cardioprotective effects of 
ALC on myocardial infarction size and cardiac 
arrhythmias in the setting of regional ischemia 
are  not  completely  understood.  Only  in  one        
in vitro study, Cui et al in 2003 investigated 
the effects of ALC on incidence of 
reperfusion-induced VF and infarct size after 
30 min global ischemia in isolated rat heart. 
Their results showed that perfusion of 0.5 and 
5 mM of ALC for 10 min before the induction 
of global ischemia (not regional ischemia) 
failed to reduce the incidence of VF (16). 
Their results also demonstrated significant 
reduction in infarct size only by the 
concentration of 5 mM ALC (16). Our results 
are consistent with the results of Cui et al in 
the case of infarct size reduction quality only. 
However, in contrast to their results, all the 
used concentrations of ALC in our model 
significantly reduced infarct size even the 
lowest concentration (0.375 mM). In addition, 
our results showed that ALC not only lowered 
VF incidence in reperfusion time but also   
lowered the number and duration of VT, 
number of VEBs, duration and incidence of 
reversible VF and total VF in both ischemia 
and reperfusion time when it was used 
throughout I/R. In our opinion some 
methodological differences between the above 
studies (ie type of ischemia and duration of 
ALC perfusion into the heart) caused different 
results by low concentrations of ALC.  
In addition, our group and other researchers 
previously reported the protective effects of     
L-carnitine (the parent compound of ALC) on 
I/R- induced cardiac arrhythmias and infarct 
size in the setting of regional ischemia in 
isolated rat heart (15, 17, 19). It seems that the 
potential cardioprotective mechanisms of ALC 
action are very similar to L-carnitine. ALC has 
important roles in fatty acids metabolism as 
well as glucose oxidation including (i) 
facilitation of beta-oxidation by transporting 
fatty acids into the mitochondria (25), (ii) 
enhancement of the metabolic flux in the 
tricarboxylic acid cycle by sparing free CoA 
(26), (iii) activation of the transport of adenine 
nucleotides across the inner mitochondrial 
membrane by preventing adenylate translocase 
inhibition by long chain acyl-CoA (27), and 
(iv) stimulation of activity of pyruvate 
dehydrogenase (PDH) by decreasing the 
mitochondrial acetyl-CoA/CoA ratio, thus 
increasing the oxidative utilization of glucose 
(28). It is important to note the vital role of 
fatty acid transport into mitochondria and its 
potential importance in regulation of Ca
2+ 
release from sarcoplasmic reticulum, because 
long chain acylcarnitines play a key role in 
arrhythmogenesis (29). It has been shown that 
long-chain acylcarnitines accumulate in 
ischemic tissue (30) and incorporate into 
cytosolic membrane compartments (31). Thus, 
long-chain acylcarnitines increase intracellular 
Ca
2+ (32) and intracellular Na
+ (33) by 
inducing cell-to-cell electrical uncoupling 
(34), and may thereby lead electrophysiologic 
and contractile dysfunction (35, 36) in the 
myocardium. Therefore, the accumulation of 
long-chain acylcarnitines under 
pathophysiologic conditions has deleterious 
consequences which are likely exacerbated by 
the influences on Ca
2+ regulatory proteins (30). 
Taken together and regarding the different 
suggested mechanisms, it seems that ALC 
protects isolated heart against I/R induced 
injuries such as arrhythmia and infarction via 
different mechanisms. Maybe, stimulation of  
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glucose oxidation and and resulting redued 
lactate and fatty acid metabolites production in 
the myocytes and scavenging of free radicals 
by ALC may have important roles in this 
condition. 
 
Conclusion 
By considering the results, it may be concluded 
that ALC has protective effects against I/R 
injuries by reduction of infarct size and 
arrhythmias in isolated rat heart when it was 
used for the whole period of 30 min regional 
ischemia followed by 120 min reperfusion. 
Future studies are required to determine the 
exact cardioprotective mechanism(s) of action 
of this agent. 
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